中国与美国罕见病药物政策对比分析
发布时间:2018-10-14 10:57
【摘要】:本文简述了罕见病及其治疗药物或称孤儿药的国内外研究现状和中国、美国罕见病治疗药物研发政策。通过对比中国与美国两国孤儿药物政策差异,分析和总结了我国孤儿药研发政策的现状。为促进我国罕见病治疗药物研发政策的建设和我国孤儿药管理制度的实施,探讨了适合我国国情的罕见病治疗药物研发和管理建议,以期对我国孤儿药的认定、立法及体制建立提供参考。
[Abstract]:In this paper, the present situation of research on rare diseases and their therapeutic drugs or orphan drugs at home and abroad and the research and development policies of rare diseases treatment drugs in China and the United States are briefly described. By comparing the differences between China and the United States, the current situation of orphan drug development policy in China is analyzed and summarized. In order to promote the construction of the policy of drug research and development for rare diseases in China and the implementation of the management system of orphan drugs in China, this paper discusses the suggestions for the development and management of drugs for the treatment of rare diseases suitable for the national conditions of our country, in order to identify the medicines for orphans in our country. The legislation and the system establishment provide the reference.
【作者单位】: 中国医学科学院北京协和医学院药物研究所 北京市药物靶点研究与新药筛选重点实验室;
【基金】:国家“重大新药创制”科技重大专项(2014ZX09507003-002,2013ZX09102106,2012ZX09103101-078)
【分类号】:R95
[Abstract]:In this paper, the present situation of research on rare diseases and their therapeutic drugs or orphan drugs at home and abroad and the research and development policies of rare diseases treatment drugs in China and the United States are briefly described. By comparing the differences between China and the United States, the current situation of orphan drug development policy in China is analyzed and summarized. In order to promote the construction of the policy of drug research and development for rare diseases in China and the implementation of the management system of orphan drugs in China, this paper discusses the suggestions for the development and management of drugs for the treatment of rare diseases suitable for the national conditions of our country, in order to identify the medicines for orphans in our country. The legislation and the system establishment provide the reference.
【作者单位】: 中国医学科学院北京协和医学院药物研究所 北京市药物靶点研究与新药筛选重点实验室;
【基金】:国家“重大新药创制”科技重大专项(2014ZX09507003-002,2013ZX09102106,2012ZX09103101-078)
【分类号】:R95
【相似文献】
相关期刊论文 前10条
1 刘玉聪;董江萍;;欧盟罕见病及孤儿药管理现状的研究[J];中国药学杂志;2012年05期
2 何江江;张崖冰;夏苏建;胡善联;;欧盟罕见病保障体系及启示[J];中国卫生政策研究;2012年07期
3 彪巍;肖永康;陈任;秦侠;马颖;胡志;;我国罕见病患者社会支持研究[J];医学与社会;2012年10期
4 李丹阳;詹文英;;中国罕见病非营利组织发展的特点和困境[J];大家健康(学术版);2013年18期
5 李定国;;罕见病防治:不仅仅是知识和技术[J];诊断学理论与实践;2014年01期
6 李秀丽;;罕见病信息传播平台的探讨与研究[J];新闻世界;2009年08期
7 吴诗瑜;张勘;;中国建立罕见病研究和防治策略的机遇与未来挑战[J];上海医药;2011年10期
8 吴诗瑜;张勘;;关于建立罕见病研究和防治策略的思考[J];中国卫生资源;2011年05期
9 林禹鸿;吴晓明;;欧盟应对罕见病政策措施及其对中国的启示[J];浙江社会科学;2011年10期
10 谷景亮;鲁艳芹;徐凌忠;;浅议我国的罕见病立法进展实践[J];卫生软科学;2013年03期
相关会议论文 前1条
1 胡娟娟;罗安琪;许q,
本文编号:2270246
本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2270246.html
最近更新
教材专著